Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

Table 1

Body weight, glycaemic, insulinaemic and lipidic profile in the lean control and diabetic ZDF rats at the initial and final time (6 weeks of vehicle or sitagliptin treatment).

Time	Initial time (20 wks)		Final time (26 wks)
Rat group	Lean control	Obese diabetic	Lean control	Obese diabetic
Parameters	(𝑛=16)	(𝑛=16)	Vehicle (𝑛=8)	Vehicle (𝑛=8)	SITA (𝑛=8)
BW (g)	406.70±6.83	388.10±8.87	445.70±8.16	354.40±8.85^aaa	380.00±14.46
Glucose (mg/dL)	133.30±1.20	523.30±3.60^aaa	133.30±1.20	633.1±15.70^aaa	546.33±19.30^bbb
HbA1c (%)	3.16±0.12	10.38±0.50^aaa	3.20±0.14	10.96±0.20^aaa	9.18±0.75^bbb
Insulin (mU/L)	15.00±5.90	13.70±0.90^aa	15.80±3.00	7.60±1.50^aaa	10.60±1.80^bbb
HOMA-Beta (%)	76.80±4.05	13.84±1.50^aaa	80.90±7.56	4.80±1.12^aaa	7.89±0.97^bbb
Total-c (mg/dL)	77.50±1.50	155.50±3.50^aaa	93.00±2.96	193.00±9.79^aaa	193.10±4.62
TGs (mg/dL)	115.00±11.00	374.50±4.95^a	154.00±19.14	400.20±27.00^aaa	237.10±22.54^bbb

Values are means ± SEM of 𝑛 rats. ^aLean control (vehicle) versus obese diabetic (vehicle) rats; ^bdiabetic SITA-treated versus diabetic untreated rats. One, two, or three letters for 𝑃<0.05, 𝑃<0.01, and 𝑃<0.001, respectively. BW: body weight; HbA1c: glycosylated haemoglobin; HOMA: homeostasis model assessment; SITA: sitagliptin; Total-c: total-cholesterol; TGs: triglycerides; ZDF: Zucker diabetic fatty.